MONTCLAIR, N.J. / ACCESSWIRE / June 04, 2014 / MetaStat, Inc. (OTCQB: MTST), a life science company focused on commercializing novel technologies that uniquely understand systemic metastasis, which is responsible for 90% of fatalities in most solid tumor cancers, announced today that positive results from a study of its MetaSite Breast test were published online in the Journal of the National Cancer Institute (JNCI). The study paper is titled “Tumor Microenvironment of Metastasis and Risk of Distant Metastasis of Breast Cancer.” The MetaSite Breast test, a diagnostic assay that quantifies the number of “tumor microenvironments of metastasis” (“TMEM” or “MetaSite”) in tumor specimens, showed a strong and statistically significant association with the risk of distant spread, or metastasis, for the most common type of breast cancer.
The study describes results from a case-control study that evaluated tumor samples from a subset of women in the Kaiser Permanente Northwest health plan that were diagnosed with invasive ductal carcinoma of the breast between 1980 and 2000. TMEM or MetaSite testing was carried out on specimens from 259 women who later developed a distant metastasis (the “Cases”) and on specimens from women who were alive and had not developed a distant metastasis (the “Controls”). Controls were individually matched with Cases so that women in each pair were the same age and were diagnosed with breast cancer in the same year.
The test performed well at assessing metastasis risk for the study’s most populous cancer subgroup: women with estrogen receptor-positive (“ER+”)/ HER2/Neu-negative (“HER2-”) disease (i.e., their cancer cells possess estrogen receptors but lack HER2 protein). Women with ER+/HER2- disease account for approximately 60 percent of all cases of breast cancer. When women with this common type of breast cancer were divided into three groups based on their TMEM score, the risk of distant metastasis turned out to be 2.7-times higher for women with tumors in the highest-scoring TMEM or MetaSite group compared with women with tumors in the lowest-scoring group. The findings confirmed results from a smaller study of the test involving 30 pairs of biopsy specimens that was published in 2009.
For comparison, TMEM predictions were compared on the same tumor samples to predictions from the IHC4 test, a diagnostic that assesses risk of recurrence by measuring levels of several proteins (ER,PR, HER2, and Ki-67) involved in tumor cell proliferation and response to hormone therapy in breast tumor tissue. As for assessing metastatic risk in the study’s most common type of breast cancer (ER+/HER2-), TMEM results were highly statistically significant while IHC4 scores were borderline significant at best. MetaStat believes this is due to its unique understanding of the mechanics and the function-based processes of tumor cell migration and entry into the bloodstream.
MetaStat is currently developing a commercially viable version of the MetaSite Breast test with automated systems to facilitate rapid repeatable implementation in a high through-put clinical lab setting. Dr. Oscar Bronsther, Chief Executive Officer of MetaStat, stated “We are thrilled to see additional positive validation of the MetaSite Breast test. We believe it confirms the path-breaking approach that our function-based diagnostics, based on the biology of the mena protein and its isoforms, provide in understanding cancer metastasis. We believe our suite of breast cancer diagnostic tests, comprised of MetaSite Breast and MenaCalc will offer women and their oncologists highly prognostic and actionable information. These diagnostic tests aim to empower patients with the information they seek to create the most personal and appropriate approach to their unique tumors."
Dr. Bronsther continued “We plan on commercializing our suite of breast cancer diagnostics in 2015 based on CLIA and GLP certification. We are excited that our commercialization efforts will be headed by industry veteran Heiner Dreissman, Ph.D., the former President and CEO of Roche Molecular Systems.”
The study was sponsored by MetaStat and was led by researchers at Albert Einstein College of Medicine of Yeshiva University (“Einstein”), Montefiore Medical Center (“Montefiore”), and the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (“MIT”). Authors of the study are: Thomas Rohan, M.D., Ph.D., Joan Jones, M.D., John Condeelis, Ph.D., Xiaonan Xue, Ph.D., and Mindy Ginsberg, B.A. of Einstein; Maja Oktay, M.D., Ph.D., and Joseph Sparano, M.D of Einstein and Montefiore; Frank Gertler, Ph.D. of MIT; Hung-Mo Lin, Sc.D., of Mount Sinai School of Medicine; and Andrew G. Glass, M.D., of Kaiser Permanente Northwest.
About MetaStat, Inc.
MetaStat is a life sciences company that develops and commercializes diagnostic products and novel therapeutics for the early and reliable prediction and treatment of systemic metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body. MetaStat is focused on breast, prostate, lung and colorectal cancers, where systemic metastasis is responsible for approximately 90% of all deaths. The company's function-based diagnostic platform technology is based on the identification and understanding of the pivotal role of the mena protein and its isoforms, a common pathway for the development of systemic metastatic disease in epithelial-based solid tumors. Both the MetaSite Breast™ and MenaCalc™ product lines are designed to accurately stratify patients based on their individual risk of metastasis and to allow clinicians to better "customize" cancer treatment decisions by positively identifying patients with a high-risk of metastasis who need aggressive therapy and by sparing patients with a low-risk of metastasis from the harmful side effects and expense of chemotherapy. Additionally, the MenaBloc™ therapeutic program aims to build upon mena biology and alternative splicing events as a driver of disease progression to exploit novel targets that provide precision medicines in oncology.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the company's Annual Report on Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the company undertakes no obligation to update such statements.
Vice President, Finance
Source: MetaStat, Inc.